Disappointment for Australian company Actinogen Medical (ASX:ACW) with the release of data from its phase 2 clinical trial (XanADu) investigating its investigative therapy Xanamem in patients with mild dementia due to Alzheimer’s disease. …
Latest Video
New Stories
-
MSAC not the 'sole solution' on gene and cell therapies
May 24, 2019 - - Latest News -
'We will not agree on how to create the demise of the other's business'
May 24, 2019 - - Latest News -
It is a very simple decision - it just involves some difficult first steps
May 24, 2019 - - Comment -
Cost recovery, resourcing and cost-offsets
May 23, 2019 - - Latest News -
HCV listing no 'Netflix' deal
May 23, 2019 - - Latest News -
Supply chain payment reform - 'mad'
May 23, 2019 - - Latest News -
Guild says doctors 'misguided and ill-informed' on flu vax
May 22, 2019 -